Board of directors
Frank Witney, PhD, served most recently as President, Chief Executive Officer of Affymetrix until its acquisition by Thermo Fisher Scientific in March 2016. Prior to that role Dr. Witney served as President and Chief Executive Officer of Dionex Corporation from April 2009 to May 2011. Dr. Witney held the position of President and Chief Executive Officer of Panomics, Inc. from July 2002 to December 2008 leading to its acquisition by Affymetrix. Prior to that role, Dr. Witney had a variety of executive positions at Bio-Rad, Packard Bioscience and PerkinElmer. Dr. Witney received a Ph.D. in Molecular and Cellular Biology from Indiana University and did post-doctoral research at the NIH. Dr. Witney is a member of the Board of Directors of Cerus Corporation and Exagen Diagnostics, Inc.
David B. Patteson
David served as Executive Chairman of Protein Technologies, Inc. He concurrently serves as President and CEO of Advion, Inc. a life science instrument business sold to Bohui Innovation Technology in 2015. David also served as CEO of Advion BioSciences, a bioanalytical CRO business acquired by Quintiles Transnational in 2011, and CEO of Biotage, Inc. acquired by Pyrosequencing AB in 2003. David holds two separate B. S. degrees from The University of Richmond and Virginia Polytechnic Institute, and completed an International Management program through IMD in Lausanne, Switzerland.
Magnus MD PhD, has 15 years of Partner level experience from Venture Capital and has been a Partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in The Bay Area in California. Magnus has a long experience in medicine, life sciences and biotech financing. He has led development teams of Phase II and III programs in the Pharmaceutical Industry. He has founded, and led private as well as public biotech and medtech companies as Chairman of the Board and Director in the Nordic Countries, Europe and USA. All in all, he has more than 90 Board years in the life science industry. Magnus has led audit and remuneration committees and several successful recruitment processes for senior management positions.
Investment Director, SLS Invest
Hans has 25 years of international experience in the life science industry. He has held various senior executive positions with Pharmacia, Pharmacia & Upjohn and Arthur D Little. He is a co-founder of the venture capital fund Innoventus which subsequently became part of SLS Invest. He is currently Vice Chairman of Oncolog Medical AB and a director of Action Pharma A/S, AdvanDx Inc, Medical Vision AB and Phasein AB. Mr Andreasson holds an M Sc in chemical engineering from Chalmers University of Technology and an MBA from INSEAD.
Herbert H. Hooper
Managing Partner, Ampersand Capital Partners
Herb, who joined Ampersand in 2002, has more than twenty years of experience working with Healthcare companies – first as an entrepreneur at Ampersand portfolio company ACLARA Biosciences, and later as an Ampersand Managing Partner. His current and past board seats include ACLARA, Bako, Signature Genomics and Viracor-IBT Laboratories. He also serves on the College of Chemistry Advisory Board for the University of California, Berkeley. Herb holds a B.S. in Chemical Engineering from North Carolina State and a Ph.D. in Chemical Engineering from the University of California, Berkeley.
Gerrit van den Dool
Gerrit, currently serves as Senior Vice President, Head of Research and Applied Solutions, Western Europe Commercial for the Life Science Business of Merck KGgA, Darmstadt. Prior to this Gerrit was Managing Director EMEA (Europe Middle East and Africa) at Sigma-Aldrich Corporation, the company he joined in 1999 and served in various sales and operational leadership roles, based in both the US and Europe. Prior to this he held a variety of positions at Amersham Pharmacia, Molecular Dynamics, Applied Biosystems and Spectra Physics. Gerrit holds an Engineering degree in Applied Physics.
David J. Parker
General Partner, Ampersand Capital Partners
Dave, who has more than 15 years of private equity experience, joined Ampersand in 1994. Dave’s board seats have included Bako, NOVEX, Signature Genomics and Roadrunner. Prior to joining Ampersand, Dave spent five years consulting at Bain and Mercer and four years in corporate lending at Bank of Boston. He holds a B.A. in Government and Economics from Dartmouth and an M.B.A. from Wharton.